Cited by 31Fatty Acid Research and HealthLipid metabolism and disordersCholesterol and Lipid Metabolism

Effect of n-3 fatty acids on metabolism of apoB100-containing lipoprotein in type 2 diabetic subjects

Open access
Ouguerram, K., Maugeais, C., Gardette, J., Magot, T., Krempf, M.·2006·British Journal of Nutrition

Abstract

The effect of long-chain n-3 PUFA on the metabolism of apoB100-containing lipoprotein in diabetic subjects is not fully understood. The objective of the present study was to determine the effect of a daily intake of 1080mg EPA and 720mg DHA for diabetic subjects on the kinetics of apoB100-containing lipoprotein in the fasting state. A kinetic study was undertaken to determine the mechanisms involved in the effects of n-3 fatty acids in terms of a decrease in triacylglycerol level in type 2 diabetic patients. We have studied the effect of fish oils on the metabolism of apoB100 endogenously labelled by [5,5,5–2H3]-leucine in type 2 diabetic patients in the fasting state. The kinetic parameters of apoB100 in VLDL, intermediate-density lipoprotein and LDL were determined by compartmental modelling in five diabetic subjects before and 8 weeks after n-3 fatty acid treatment. Treatment did not change the plasma cholesterol level (0·801 (sd 0·120)v. 0·793 (sd 0·163) mmol/l) but lowered the plasma triacylglycerol level (1·776 (sd 0·280) v.1·356 (sd 0·595) mmol/l; p<0·05). Treated patients showed a decrease in VLDL apoB100 concentration (0·366 (sd 0·030) v.0·174 (sd 0·036) g/l; v<0·05) related to a decrease in VLDL 1 production (1·49 (sd 0·23) v.0·44 (sd 0·19) mg/kg per h; p<0·05) and an increase in the VLDL conversion rate (0·031 (sd 0·024)v.0·052 (sd 0·040) per h; p<0·05), with no change in fractional catabolic rates. Treatment led to a higher direct production of intermediate-density lipoprotein (0·02 (sd 0·01) v 0·24 (sd 0·12) mg/kg per h; p<0·05). In conclusion, the present study, conducted in the fasting state, showed that supplementation with n-3 fatty acids in type 2 diabetic patients induced beneficial changes in the metabolism of apoB100-containing lipoprotein.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1079/bjn20061806

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ouguerram, K., Maugeais, C., Gardette, J., Magot, T., & Krempf, M.
Affiliations
  • Inserm (FR)
  • F. Hoffmann-La Roche AG (CH)
Corresponding author
Ouguerram, K.
Venue
British Journal of Nutrition
Published
2006-01
Volume
96
Issue
1
Pages
100-106
ISSN
  • 0007-1145 (ISSN-L)
  • 1475-2662
OpenAlex
W2118132337
Cited by
31
References
48
Citations by year
2025: 4 · 2024: 2 · 2022: 1 · 2021: 1 · 2020: 3 · 2018: 2 · 2017: 2 · 2016: 2 · 2014: 2 · 2013: 2 · 2012: 1
FWCI
1.76
Type
journal article
Language
en
Open access
Locations
  • British Journal Of Nutrition (publishedVersion)
  • PubMed (publishedVersion)
  • reroDoc Digital Library (submittedVersion)
Funders
Les Laboratories Pierre Fabre
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
omega-3 fatty acids, omega-3 polyunsaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid, fish oil supplementation, type 2 diabetes, lipoprotein kinetics, intermediate density lipoprotein, triglycerides, serum cholesterol, fractional catabolic rate, fractional synthesis rate, compartmental modeling
MeSH terms
Adolescent, Adult, Aged, Apolipoproteins B, Diabetes Mellitus, Type 2, Dietary Proteins, Docosahexaenoic Acids, Fish Oils, Humans, Lipoproteins, Lipoproteins, LDL, Lipoproteins, VLDL, Middle Aged, Models, Biological, Triglycerides, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Apolipoprotein B-100, Lipoproteins, IDL

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review